Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Recruiting Not applicable

Mobile Phone-Based Smoking-Cessation Intervention for Smoking Parents

NCT06570122 · tracked via the Priya Life Science China tracker
Phase
Not applicable
Started
2025-09-01
Last updated
2026-09-02

Condition(s) studied

Smoking Cessation

Investigational drug(s) / intervention(s)

5A's/5R's adviceHealth warning leafletAI-powered chatbot support

5A's/5R's advice: 5A's (Ask, Advise, Assess, Assist, Arrange) for smokers who are ready to quit, and 5R's (relevance, risks, rewards, roadblocks, and repetition) for smokers who are not ready to quit.

Health warning leaflet: The health warning leaflet provides essential information on the dangers of secondhand and thirdhand smoke. It outlines how exposure to these forms of smoke can harm both smokers and non-smokers, particularly children, by increasing the risk of respiratory illnesses and other health issues.

AI-powered chatbot support: Participants will receive three months of AI-powered chatbot, equipped with personalized interactions and real-time support, via WeChat.

Study summary

This study aims to explore the feasibility and preliminary effectiveness of a mobile phone-based intervention tailored specifically for smoking parents.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
Accepted
Inclusion Criteria: 1. aged 18 and above, reside in Zhuhai for the next 6 months 2. smoke at least 1 cigarette or use e-cigarettes daily 3. have a smartphone and a WeChat account, able to use WeChat skillfully Exclusion Criteria: 1. Smokers who have communication barrier (either physically or cognitively) 2. Smokers who are currently participating in other SC programmes or services

Primary outcome measure(s)

  • Self-reported 7-day point prevalence quit rate — 3 and 6 months follow-up
    Self-reported 7-day point prevalence quit rate in the two groups
  • Eligibility rate — baseline
    the percentage of eligible smokers out of the total number of smokers screened

Trial sites (1)

FacilityCityRegionStatus
Beijing Normal University Zhuhai Guangdong Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06570122 on ClinicalTrials.gov ↗ ← All trials in China